

POSTER SESSIONS

Poster Halls open from 7 am to 7 pm; all posters will be available for viewing for the duration of the conference

	MONDAY 2/28/11 • 2-4 PM	TUESDAY 3/1/11 • 2-4 PM	WEDNESDAY 3/2/11 • 2-4 PM
HALL D	<p>50. HIV Entry and Cell–Cell Transmission (174-184)</p> <p>52. Nuclear Import, Integration, and Latency (191-199)</p> <p>57. Viral Evolution and Host Adaptation (232-234)</p> <p>59. Insights from Pathogenic vs Non-pathogenic Infections (242-246)</p> <p>60. Animal Models of HIV/SIV Pathogenesis (247-255)</p> <p>61. Cellular Consequences of HIV Infection (256-259)</p> <p>62. How HIV Affects Different CD4 T Cell Subsets (260-265)</p> <p>63. What's New with PD-1 (266-268)</p> <p>73. What's New with NK Cells (325-327)</p> <p>74. Innate Immunity (328-330)</p> <p>75. CD4 T Cell Responses (331-334)</p> <p>81. Preclinical Testing of New Vaccine Concepts (358-366)</p> <p>84. Cytokine Therapies for SIV/HIV Infection (374-378)</p> <p>88. Predictors of HIV-associated Neurological Disease (390-402)</p> <p>91. Neuropathy (414-420)</p> <p>101. Factors Affecting HIV Transmission (482-489)</p> <p>104. Primary/Acute HIV Infection (508-517)</p>	<p>51. NEF, Tetherin, and Vpu (185-190)</p> <p>55. XMRV: New Findings and Controversies (215-223)</p> <p>58. XMRV and GBV Virus–Host Interaction (235-241)</p> <p>64. Immune Reconstitution in the 21st Century (269-275)</p> <p>65. Viral Dynamics on Raltegravir Intensification (276-281)</p> <p>66. Studies of Chronic Infection (282-288)</p> <p>67. New Insights from Superinfection (289-290)</p> <p>68. Insights from Studies of Non-progressive Infection (291-296)</p> <p>76. Neutralizing vs ADCC Antibodies (335-337)</p> <p>77. Neutralizing Antibodies to gp41 (338-342)</p> <p>78. Neutralizing Antibodies to gp120 (343-346)</p> <p>82. Choosing the Best Immunogen (367-370)</p> <p>85. Antibodies as Therapy (379-380)</p> <p>86. Targeting Immune Activation (381-383)</p> <p>89. Biomarkers Linked to Cognitive Dysfunction (403-409)</p> <p>92. Therapy of HIV Neurological Disease and CNS Penetration (421-429)</p> <p>94. Imaging of HIV Neurological Disease (441-450)</p> <p>95. Molecular Epidemiology: Primate Viruses and How They Affect Humans (451-454)</p> <p>96. Molecular Epidemiology: Simian Viruses in South America (455)</p> <p>102. Viral Genetics of Transmission (490-497)</p>	<p>53. Uncoating, Reverse Transcription, and Assembly (200-204)</p> <p>54. TRIM5, APOBEC, and Other Host Restriction Factors (205-214)</p> <p>56. HIV Replication and Restriction in Macrophages (224-231)</p> <p>69. The Latest on Cytokine Disruption (297-301)</p> <p>70. The Latest on Immune Activation (302-312)</p> <p>71. Microbial Translocation and Immune Activation in HIV Infection and Therapy (313-320)</p> <p>72. How the Gut Affects Pathogenesis (321-324)</p> <p>79. CD8 T Cells and Virus Inhibition (347-350)</p> <p>80. CD8 T Cell Cytolytic and Cytokine Function (351-357)</p> <p>83. Phase I Human Trials of New Vaccine Strategies (371-373)</p> <p>87. New Results from Therapeutic Vaccine Trials (384-389)</p> <p>90. NeuroAIDS in Acute Infection (410-413)</p> <p>93. HIV Neuropathogenesis: Immune Activation, Stress, Response, and Viral Replication in the Brain (430-440)</p> <p>97. Molecular Epidemiology: Transmission and Evolution (456-465)</p> <p>98. Molecular Epidemiology: HTLV-1 (466)</p> <p>99. Host Genomics (467-474)</p> <p>100. Genomics and Pharmacogenetics: HIV Disease Progression, ARV Toxicity, and Response to HCV Therapy (475-481)</p> <p>103. Mechanisms of Sexual HIV Transmission (498-507)</p>
HALL A	<p>105. New ARV Agents, Targets, and Formulations (518-532)</p> <p>112. Mechanisms of Resistance to Novel Entry Inhibitors (585-588)</p> <p>113. Co-receptor Usage, Resistance to CCR5 Inhibitors, and Treatment Responses (589-593)</p> <p>114. New Insights into NNRTI Resistance (594-598)</p> <p>120. Pharmacokinetics and Drug Interactions of New and Existing ARV Agents (627-637)</p> <p>123. Diagnostic Algorithms (651-655)</p> <p>131. Cotrimoxazole for HIV and Malaria in Children (687-689)</p> <p>135. HIV and ART-related Complications in Children and Youth (698-700)</p> <p>136. Cardiovascular Complications and Dyslipidemias in Children and Youth (701-704)</p> <p>137. Bone Complications and Treatment in Children and Youth (705-707)</p> <p>140. HIV Drug Resistance and Tropism after Treatment Failure in Children (720-722)</p> <p>141. Viral and Host Factors Associated with Pediatric HIV Infection (723-724)</p> <p>144. Host Factors Associated with MTCT (732-734)</p> <p>145. Risk Factors for MTCT (735-738)</p>	<p>106. ART Strategies and Predictors of Response (533-547)</p> <p>117. Novel Resistance Mechanisms, Assays, and Interpretations (609-615)</p> <p>118. Resistance Profiles after First-line Therapy (616-618)</p> <p>119. Is HIV Drug Resistance Spreading? (619-626)</p> <p>121. Clinical Pharmacology in Special Populations and Compartments (638-645)</p> <p>124. Nucleic Acid Detection (656-661)</p> <p>125. Drug Resistance Testing (662-665)</p> <p>129. Pediatric Retention and Outcomes in Resource-limited Settings (680-684)</p> <p>130. Cost and Impact of Pediatric Prevention and ART Programs in Resource-limited Settings (685-686)</p> <p>132. Risk Factors for HIV Acquisition among Youth (690-691)</p> <p>133. ART Use and Outcomes among Youth (692-695)</p> <p>134. HIV Disclosure in Children and Youth (696-697)</p> <p>150. ART Pharmacokinetics during Pregnancy and Infancy (754-757)</p> <p>151. Incidence and Prevention of PMTCT-associated Drug Resistance (758-761)</p> <p>152. HPV Prevalence and Cervical Cancer Treatment (762-768)</p> <p>153. Factors Associated with HIV Replication or Susceptibility in Women (769-778)</p> <p>154. Cervical Cancer Screening in the Developing World: Lessons from Africa (779-783)</p>	<p>107. ART Outcomes (548-559)</p> <p>108. ART Outcomes and Coverage in Resource-limited Settings (560-568)</p> <p>109. HIV-1 Subtypes, Viremia, and Immune Activation (569-571)</p> <p>110. CD4 Cell Responses, Immune Activation, and Low-level Viremia (572-577)</p> <p>111. ARV Switching (578-584)</p> <p>115. Novel Insights into Protease Inhibitor Resistance (599-605)</p> <p>116. Mechanisms of Raltegravir Resistance (606-608)</p> <p>122. Pharmacologic Considerations for Therapeutic Success or Failure in Resource-limited Settings (646-650)</p> <p>126. Tropism Assays (666-671)</p> <p>127. CD4 Assays (672-674)</p> <p>128. Laboratory Monitoring of ART in Resource-limited Settings (675-679)</p> <p>138. Lopinavir/Ritonavir Pharmacokinetics, Safety, and Efficacy in Children (708-711)</p> <p>139. ART Pharmacokinetics in Children (712-719)</p> <p>142. Immune Response to Perinatal HIV and ART (725-728)</p> <p>143. Response to Protective Vaccines in Children and Youth (729-731)</p> <p>146. ARV Regimens and Prevention of MTCT (739-742)</p> <p>147. HAART during Pregnancy and Pre-term Delivery (743-746)</p> <p>148. PMTCT: Child Health Outcomes (747-751)</p> <p>149. PMTCT: Maternal Health and Treatment Outcomes (752-753)</p> <p>155. HIV Services, Diabetes, and Disease Progression in Women (784-788)</p>
HALL B	<p>156. Causes of Death in Treated HIV (789-791)</p> <p>157. Aging and HIV (792-795)</p> <p>158. Inflammation and Coagulation (796-800)</p> <p>159. Cardiovascular Disease: Outcomes and Predictors (801-808)</p> <p>160. Atherosclerosis and HIV: Risk Factors and Pathogenesis (809-814)</p> <p>172. HPV and Anal Cancer (870-873)</p> <p>173. KSHV and Kaposi's Sarcoma (874-875)</p> <p>180. HCV: Epidemiology and Diagnosis (911-920)</p> <p>181. HCV: Natural History (921-929)</p> <p>182. HCV: Immunology (930-935)</p> <p>193. Sexually Transmitted Infections: HSV-2 and Syphilis (979-981)</p> <p>194. Topical and Oral PrEP: Preclinical and Animal Model Studies (982-989)</p> <p>195. Clinical and Modeling Studies of Oral and Topical PrEP (990-1004)</p> <p>196. Male Circumcision: Scale-up and Impact (1005-1008)</p> <p>199. Community Viral Load (1022-1025)</p> <p>200. HIV Transmission: Risk Factors and Rates (1026-1033)</p> <p>201. Changing HIV Risk Behaviors (1034-1043)</p> <p>202. Understanding HIV Transmission Networks (1044-1047)</p>	<p>161. Abacavir and Studies of Inflammatory Markers and Leukocyte Adhesion (815-816)</p> <p>162. ART and Lipid Changes: Randomized Clinical Trials (817-821)</p> <p>163. Shedding Some More Light on Vitamin D and HIV (822-829)</p> <p>164. Bone Disease: Fracture Risk and ART (830-835)</p> <p>174. TB: Diagnosis and Case Finding (876-880)</p> <p>175. TB: ART and Outcomes (881-888)</p> <p>176. HIV, TB, and Malaria in Resource-limited Settings (889-891)</p> <p>184. HCV: Viral Pathogenesis and <i>in vitro</i> Studies (940-942)</p> <p>185. HCV and HBV Genetics (943-951)</p> <p>186. HCV Treatment: Direct Acting Agents and Resistance (952-957)</p> <p>187. HCV Treatment: Interferon and Ribavirin (958-964)</p> <p>188. HCV: Treatment Impact (965-967)</p> <p>203. Improving Knowledge of HIV Serostatus (1048-1055)</p> <p>204. Identifying Recent HIV Infections (1056-1063)</p> <p>207. Understanding HIV Disease Progression (1082-1084)</p>	<p>165. Renal Disease: Long-term Outcomes and Prognostic Factors (836-843)</p> <p>166. Lipohypertrophy and Fat Loss (844-847)</p> <p>167. Diabetes Mellitus and Glucose Metabolism (848-850)</p> <p>168. Hyperlactatemia and Pancreatitis (851-853)</p> <p>169. IRIS: Immunologic Predictors (854-858)</p> <p>170. Hematologic Malignancies (859-863)</p> <p>171. Cancer Epidemiology (864-869)</p> <p>177. Cryptococcal Meningitis and Other Cryptic Diseases (892-896)</p> <p>178. Opportunistic and Other Infections: Diverse Aspects (897-904)</p> <p>179. HIV 1 Year Later (905-910)</p> <p>183. HCV: Microbial Translocation (936-939)</p> <p>189. HBV: Natural History (968-970)</p> <p>190. HBV: Vaccination (971-972)</p> <p>191. HBV: Delta (973-974)</p> <p>192. HBV: Treatment (975-978)</p> <p>197. Recruitment and Retention of High-risk Populations: Enhancing Prevention and Linkage to Care (1009-1013)</p> <p>198. Retention and Adherence to Care in Resource-limited Settings (1014-1021)</p> <p>205. Linking HIV-infected Persons to Care (1064-1072)</p> <p>206. HIV Testing and Linkage to Care in Resource-limited Settings (1073-1081)</p>